Quantum-Si Honored as Proteomics Company of the Year by the BioTech Breakthrough Awards streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
News Category Global Banking & Finance Reviews
Sengenics Awarded Prestigious Michael J. Fox Foundation Grant to Determine the Role of Autoantibodies in the Progression of Parkinson’s
Sengenics Awarded Prestigious Michael J. Fox Foundation Grant to Determine the Role of Autoantibodies in the Progression of Parkinson’s Sengenics, the Functional Proteomics Company, has been awarded a prestigious research grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify novel autoantibody signatures related to non-motor symptoms in individuals with high risk of Parkinsons disease (PD) from the Parkinsons Associated Risk Study (PARS). The objective of the study will be to leverage KREX-based Immunome protein arrays to identify autoantibodies that may have potential as diagnostic or mechanistic biomarkers and, furthermore, to help in understanding the aetiology of PD in terms of pathogenesis and disease progression. Sengenics will be the first external partner in
Dec 15, 2020 14:00 UTC
Sengenics Awarded Prestigious Michael J. Fox Foundation Grant to Determine the Role of Autoantibodies in the Progression of Parkinson’s LONDON (Business Wire) Sengenics, the Functional Proteomics Company, has been awarded a prestigious research grant by The Michael J. Fox Foundation for Parkinson s Research (MJFF) to identify novel autoantibody signatures related to non-motor symptoms in individuals with high risk of Parkinson’s disease (PD) from the Parkinson’s Associated Risk Study (PARS). The objective of the study will be to leverage KREX-based Immunome protein arrays to identify autoantibodies that may have potential as diagnostic or mechanistic biomarkers and, furthermore, to help in understanding the aetiology of PD in terms of pathogenesis and disease progression. Sengenics will be the first external partner in the world to gain access to the PARS cohort.